Gilead Science Selects Viread As Tradename For HIV Therapy Tenofovir DF
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Gilead Sciences has chosen the brandname Viread for its HIV therapy tenofovir disoproxil fumarate. An NDA was submitted May 1 for the oral, once-daily nucleotide reverse transcriptase inhibitor and is receiving priority review.